CHGC.F Stock Overview
Engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Chugai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥41.15 |
| 52 Week High | JP¥52.22 |
| 52 Week Low | JP¥29.75 |
| Beta | 0.48 |
| 1 Month Change | -9.46% |
| 3 Month Change | -6.50% |
| 1 Year Change | 17.37% |
| 3 Year Change | 17.54% |
| 5 Year Change | -58.85% |
| Change since IPO | 169.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| CHGC.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 6.2% | 1.3% | 0.6% |
| 1Y | 17.4% | 1.2% | 22.4% |
Return vs Industry: CHGC.F exceeded the US Pharmaceuticals industry which returned 0.5% over the past year.
Return vs Market: CHGC.F underperformed the US Market which returned 22.7% over the past year.
Price Volatility
| CHGC.F volatility | |
|---|---|
| CHGC.F Average Weekly Movement | 16.7% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CHGC.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CHGC.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1925 | 7,604 | Osamu Okuda | www.chugai-pharm.co.jp |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology.
Chugai Pharmaceutical Co., Ltd. Fundamentals Summary
| CHGC.F fundamental statistics | |
|---|---|
| Market cap | US$71.39b |
| Earnings (TTM) | US$2.54b |
| Revenue (TTM) | US$7.67b |
28.1x
P/E Ratio9.3x
P/S RatioIs CHGC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHGC.F income statement (TTM) | |
|---|---|
| Revenue | JP¥1.17t |
| Cost of Revenue | JP¥339.41b |
| Gross Profit | JP¥831.20b |
| Other Expenses | JP¥443.89b |
| Earnings | JP¥387.32b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 24, 2025
| Earnings per share (EPS) | 235.38 |
| Gross Margin | 71.01% |
| Net Profit Margin | 33.09% |
| Debt/Equity Ratio | 0% |
How did CHGC.F perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield42%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/05 04:16 |
| End of Day Share Price | 2025/02/05 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chugai Pharmaceutical Co., Ltd. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Siti Bte Salikin | CFRA Equity Research |